Postoperative complications and oncologic outcomes after multimodal therapy of localized high risk soft tissue sarcoma.
Humans
Wound Healing
/ radiation effects
Postoperative Complications
/ epidemiology
Combined Modality Therapy
Radiotherapy, Adjuvant
/ adverse effects
Neoadjuvant Therapy
/ adverse effects
Diabetes Mellitus
/ etiology
Extremities
/ pathology
Sarcoma
/ pathology
Soft Tissue Neoplasms
/ pathology
Wound Infection
/ complications
Retrospective Studies
Multimodal therapy
Postoperative complications
Radiotherapy
Soft tissue sarcoma
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
21 Dec 2022
21 Dec 2022
Historique:
received:
26
07
2022
accepted:
21
11
2022
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Standard therapy for localized high-risk soft tissue sarcoma includes surgical resection and neoadjuvant or adjuvant radiation therapy (± chemotherapy and locoregional hyperthermia). No difference in oncologic outcomes for patients treated with neoadjuvant and adjuvant radiation therapy was reported, whereas side effect profiles differ. The aim of this analysis was to analyse oncologic outcomes and postoperative complications in patients treated with multimodal treatment. Oncologic outcomes and major wound complications (MWC, subclassified as wound healing disorder, infection, abscess, fistula, seroma and hematoma) were evaluated in 74 patients with localized high-risk soft tissue sarcoma of extremities and trunk undergoing multimodal treatment, and also separately for the subgroup of lower extremity tumors. Clinical factors and treatment modalities (especially neoadjuvant vs. adjuvant radiotherapy) were evaluated regarding their prognostic value and impact on postoperative wound complications. Oncologic outcomes were dependent on number of high risk features (tumor size, depth to superficial fascia and grading), but not on therapy sequencing (however with higher risk patients in the neoadjuvant group). Different risk factors influenced different subclasses of wound healing complications. Slightly higher MWC-rates were observed in patients treated with neoadjuvant therapy, compared to adjuvant radiotherapy, although only with a trend to statistical significance (31.8% vs. 13.3%, p = 0.059). However, except for wound infections, no significant difference for other subclasses of postoperative complications was observed between neoadjuvant and adjuvant therapy. Diabetes was confirmed as a major risk factor for immune-related wound complications. Rates of major wound complications in this cohort are comparable to published data, higher rates of wound infections were observed after neoadjuvant radiotherapy. Tumor localization, patient age and diabetes seem to be major risk factors. The number of risk factors for high risk soft tissue sarcoma seem to influence DMFS. Neoadjuvant treatment increases the risk only for wound infection treated with oral or intravenous antibiotic therapy and appears to be a safe option at an experienced tertiary center in absence of other risk factors.
Sections du résumé
BACKGROUND
BACKGROUND
Standard therapy for localized high-risk soft tissue sarcoma includes surgical resection and neoadjuvant or adjuvant radiation therapy (± chemotherapy and locoregional hyperthermia). No difference in oncologic outcomes for patients treated with neoadjuvant and adjuvant radiation therapy was reported, whereas side effect profiles differ. The aim of this analysis was to analyse oncologic outcomes and postoperative complications in patients treated with multimodal treatment.
METHODS
METHODS
Oncologic outcomes and major wound complications (MWC, subclassified as wound healing disorder, infection, abscess, fistula, seroma and hematoma) were evaluated in 74 patients with localized high-risk soft tissue sarcoma of extremities and trunk undergoing multimodal treatment, and also separately for the subgroup of lower extremity tumors. Clinical factors and treatment modalities (especially neoadjuvant vs. adjuvant radiotherapy) were evaluated regarding their prognostic value and impact on postoperative wound complications.
RESULTS
RESULTS
Oncologic outcomes were dependent on number of high risk features (tumor size, depth to superficial fascia and grading), but not on therapy sequencing (however with higher risk patients in the neoadjuvant group). Different risk factors influenced different subclasses of wound healing complications. Slightly higher MWC-rates were observed in patients treated with neoadjuvant therapy, compared to adjuvant radiotherapy, although only with a trend to statistical significance (31.8% vs. 13.3%, p = 0.059). However, except for wound infections, no significant difference for other subclasses of postoperative complications was observed between neoadjuvant and adjuvant therapy. Diabetes was confirmed as a major risk factor for immune-related wound complications.
CONCLUSION
CONCLUSIONS
Rates of major wound complications in this cohort are comparable to published data, higher rates of wound infections were observed after neoadjuvant radiotherapy. Tumor localization, patient age and diabetes seem to be major risk factors. The number of risk factors for high risk soft tissue sarcoma seem to influence DMFS. Neoadjuvant treatment increases the risk only for wound infection treated with oral or intravenous antibiotic therapy and appears to be a safe option at an experienced tertiary center in absence of other risk factors.
Identifiants
pubmed: 36544149
doi: 10.1186/s13014-022-02166-4
pii: 10.1186/s13014-022-02166-4
pmc: PMC9768905
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Deutsche Krebshilfe
ID : 70114187
Informations de copyright
© 2022. The Author(s).
Références
Eur J Surg Oncol. 2014 Dec;40(12):1671-6
pubmed: 25456440
Oncol Lett. 2015 Aug;10(2):841-844
pubmed: 26622580
Nurs Clin North Am. 1990 Mar;25(1):247-61
pubmed: 2179891
Clin Orthop Relat Res. 2013 Nov;471(11):3612-7
pubmed: 23813183
Eur J Surg Oncol. 2018 Jun;44(6):816-822
pubmed: 29472042
Adv Skin Wound Care. 2003 Nov;16(6):291-4
pubmed: 14652514
Chirurg. 2000 Jul;71(7):787-94
pubmed: 10986600
Clin Orthop Relat Res. 2010 Nov;468(11):3003-11
pubmed: 20645035
Ann Surg. 1994 Feb;219(2):165-73
pubmed: 8129487
J Plast Reconstr Aesthet Surg. 2021 Oct;74(10):2443-2457
pubmed: 34266806
J Clin Oncol. 1996 Mar;14(3):869-77
pubmed: 8622035
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
Am J Clin Oncol. 2012 Feb;35(1):13-7
pubmed: 21278563
Ann Surg Oncol. 2018 Mar;25(3):754-767
pubmed: 28895107
BMC Cancer. 2003 May 26;3:17
pubmed: 12769830
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1112-6
pubmed: 12829149
Ann Surg Oncol. 2006 Sep;13(9):1209-15
pubmed: 16952046
Surgery. 1987 Sep;102(3):447-52
pubmed: 3629473
PLoS One. 2011;6(8):e20294
pubmed: 21826194
Ann Surg Oncol. 2013 May;20(5):1494-9
pubmed: 23242820
J Plast Reconstr Aesthet Surg. 2019 Sep;72(9):1449-1464
pubmed: 31302071
Cancer. 2006 Nov 15;107(10):2455-61
pubmed: 17036354
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e525-8
pubmed: 21676552
J Visc Surg. 2015 Sep;152(4):223-30
pubmed: 26088366
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):482-8
pubmed: 12738324
Am J Clin Oncol. 2018 Oct;41(10):1019-1023
pubmed: 29315173
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Clin Orthop Relat Res. 2007 Jun;459:182-5
pubmed: 17452922
J Surg Oncol. 1996 Feb;61(2):90-9
pubmed: 8606553
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Int J Hyperthermia. 2018 Nov;34(7):980-987
pubmed: 28826283
Infect Control Hosp Epidemiol. 2016 Jan;37(1):88-99
pubmed: 26503187
Eur J Cancer. 1994;30A(6):746-51
pubmed: 7917531
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Innov Surg Sci. 2017 Dec 06;2(4):165-170
pubmed: 31579750
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1595-9
pubmed: 1938569
Ann Surg Oncol. 2015 Sep;22(9):2869-75
pubmed: 25783679
Cancer. 2012 Dec 1;118(23):5867-77
pubmed: 22648518
Radiother Oncol. 2005 Apr;75(1):48-53
pubmed: 15948265
Ann Surg Oncol. 2014 Aug;21(8):2463-5
pubmed: 24838365
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Indian J Orthop. 2018 Jan-Feb;52(1):35-44
pubmed: 29416168
Drugs Aging. 2001;18(8):607-20
pubmed: 11587247
Ann Surg Oncol. 2010 May;17(5):1367-74
pubmed: 20217260